Page 3 - Sun Pharma

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Six-day work weeks won't work anymore for new talent, says report

According to a report, companies with 6-day work weeks have to settle for leftover talent

Drug makers Glenmark, Sun Pharma, Dr Reddy's recall products in US

Leading generic drug makers Glenmark, Sun Pharma, Dr Reddy's and Jubilant Cadista are recalling multiple products in the US market, the world's largest market for medicines, for various issues

Sun Pharma stock likely to keep shining amid global specialty scale-up

Focus on key markets to help expand branded formulations business, say experts

We continue to increase our reach and access in India, say Sun Pharma execs

Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more

Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

Sun Pharma shares jump over 5% after firm's Q1 net profit rises 43%

Shares of Sun Pharma on Friday jumped over 5 per cent after the company reported a 43 per cent rise in consolidated net profit for the June quarter. The stock climbed 5.45 per cent to settle at Rs 943.55 apiece on the BSE. During the day, it rallied 6.31 per cent to Rs 951.25. On the NSE, it jumped 5.44 per cent to Rs 943.60 apiece. In volume terms, 4.88 lakh shares were traded on the BSE and over 1.13 crore shares on the NSE during the day. On Friday, Sun Pharma reported a 43 per cent rise in consolidated net profit at Rs 2,061 crore for the June quarter, riding on robust sales across markets. The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June period of 2021-22. Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing. The 30-share BSE barometer jumped 712.46 points or 1.25 per cent to settle at 57,570.25.

Top headlines: HDFC Q1 net rises 22%; IOC posts Rs 1,993-cr net loss in Q1

Swiggy announced on Friday that it has extended its 'Future of Work' policy and announced a permanent work-from-anywhere for majority of roles.

Sensex rises 712 pts, Nifty tops 17,150; Tata Steel rallies 7%, HDFC 2%

CLOSING BELL: Public sector banks were the only losers with the Nifty PSB index down 1.2 per cent

Sun Pharma Q1 net profit soars 43% YoY to Rs 2,061 cr; revenue up 10%

It has reported an Ebitda (earnings before interest, tax, depreciation and ammortisation) of Rs 2,884 crore (including other operating revenues), with the Ebitda margin at 26.8 per cent.

Stocks to watch: HDFC, Sun Pharma, Dr Reddy's, STFC, TVS Motor, SpiceJet

Stocks to watch today: HDFC, Sun Pharma, and Cipla will report their June quarter results on Friday, July 29; Dr Reddy's saw 108 per cent YoY rise in consolidated net profit to Rs 1,187.6 crore in Q1.

Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,445 crores in the year-ago quarter.

Stocks to watch: Infosys, RIL, ICICI Bank, YES Bank, Glenmark, Tata Motors

Stocks to watch today: Axis Bank, Tata Steel will report their June quarter 2022 results (Q1FY23) on Monday, July 25; Infosys delivered net profit for Q1 below street expectations at Rs 5,360 crore.

Sun Pharma, Glenmark recall products in US due to manufacturing issues

Leading drug makers Sun Pharma and Glenmark are recalling products in the US, the world's largest market for medicines, due to lapses in the manufacturing process. As per the latest enforcement report by the US Food and Drug Administration (USFDA), a US-based unit of Sun Pharma is recalling 50,680 vials of Testosterone Cypionate Injection, used to treat low testosterone in adult males, in the American market. According to the US health regulator, the Mumbai-based drug major is recalling the affected lot due to "water leakage" leading to deviation from current good manufacturing practices (cGMP). The company is also recalling 27 vials of the same medication due to cGMP deviations, USFDA said. "Manufacturing deviations were reported due to an abnormal appearance on parts of machinery," it added. The affected lot was produced at Sun Pharma's Halol (Gujarat) based manufacturing plant. New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the company, initiated the Class II ...

ITC, Sun Pharma: 5 defensive stocks that may gain up to 25%. You own any?

Pharma stocks like Torrent Pharmaceuticals, Sun Pharmaceutical Industries, and Cipla can easily run up to 18 per cent

Sun Pharma plans to expand field force in India by 10% this fiscal

The Mumbai-based drug major currently employs around 11,000 Medical Representatives and related staff in India

Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts

Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million

From DRL to Glenmark, pharma companies see steady revenue growth in Russia

Strong sales in Q4 during war aided by 'stocking up of inventory'

Sun Pharma slips 4% on posting Rs 2,277 crores loss in Q4

The loss came on account of settlement charges of pending litigations in the US, and restructuring operations in some countries. Adjusted profit grew 18 per cent year on year (YoY) to Rs 1,582 crore.